Study on the effects and mechanisms of Lycium ruthenicum Murr. in improving sleep
- VernacularTitle:黑果枸杞改善睡眠的作用及机制研究
- Author:
Ming QIAO
1
;
Yao ZHAO
2
;
Yi ZHU
1
;
Yexia CAO
3
;
Limei WEN
1
;
Yuehong GONG
1
;
Xiang LI
4
;
Juanchen WANG
4
;
Tao WANG
4
;
Jianhua YANG
1
;
Junping HU
3
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Xinjiang Medical University，Urumqi 830011，China;Xinjiang Key Laboratory of Clinical Drug Research，Urumqi 830011，China
2. Dept. of Pharmacy，the First Affiliated Hospital of Xinjiang Medical University，Urumqi 830011，China
3. College of Pharmacy，Xinjiang Medical University，Urumqi 830017，China
4. Xinjiang Black Wolfberry Biotechnology Co.，Ltd.，Xinjiang Korla 841009，China
- Publication Type:Journal Article
- Keywords:
Lycium ruthenicum Murr.;
improving sleep;
insomnia;
network pharmacology;
zebrafish
- From:
China Pharmacy
2026;37(1):24-29
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the effects and mechanisms of Lycium ruthenicum Murr. in improving sleep. METHODS Network pharmacology was employed to identify the active components of L. ruthenicum and their associated disease targets， followed by enrichment analysis. A caffeine‑induced zebrafish model of sleep deprivation was established ， and the zebrafish were treated with L. ruthenicum Murr. extract （LRME） at concentrations of 0.1， 0.2 and 0.4 mg/mL， respectively； 24 h later， behavioral changes of zebrafish and pathological alterations in brain neurons were subsequently observed. The levels of inflammatory factors [interleukin-6 （IL-6）， IL-1β， IL-10， tumor necrosis factor-α （TNF-α）]， oxidative stress markers [superoxide dismutase （SOD）， malondialdehyde （MDA）， glutathione peroxidase （GSH-Px）， catalase （CAT）]， and neurotransmitters [5- hydroxytryptamine （5-HT）， γ-aminobutyric acid （GABA）， glutamic acid （Glu）， dopamine （DA）， and norepinephrine （NE）] were measured. The protein expression levels of protein kinase B1 （AKT1）， phosphorylated AKT1 （p-AKT1）， epidermal growth factor receptor （EGFR）， B-cell lymphoma 2 （Bcl-2）， sarcoma proto-oncogene，non-receptor tyrosine kinase （SRC）， and heat shock protein 90α family class A member 1 （HSP90AA1） in the zebrafish were also determined. RESULTS A total of 12 active components and 176 intersecting disease targets were identified through network pharmacology analysis. Among these， apigenin， naringenin and others were recognized as core active compounds， while AKT1， EGFR and others served as key targets； EGFR tyrosine kinase inhibitor resistance signaling pathway was identified as the critical pathway. The sleep improvement rates in zebrafish of LRME low-， medium-， and high-dose groups were 54.60%， 69.03% and 77.97%， 开发。E-mail：hjp_yft@163.com respectively， while the inhibition ratios of locomotor distance were 0.57， 0.83 and 0.95， respectively. Compared with the model group， the number of resting counts， resting time and resting distance were significantly increased/extended in LRME medium- and high-dose groups （P＜0.05）. Neuronal damage in the brain was alleviated. Additionally， the levels of IL-6， IL-1β， TNF-α， MDA， Glu， DA and NE， as well as the protein expression levels of AKT1， p-AKT1， EGFR， SRC and HSP90AA1， were markedly reduced （P＜0.05）， while the levels of IL-10， SOD， GSH-Px， CAT， 5-HT and GABA， as well as Bcl-2 protein expression， were significantly elevated （P＜0.05）. CONCLUSIONS L. ruthenicum Murr. demonstrates sleep-improving effects， and its specific mechanism may be related to the regulation of inflammatory responses， oxidative stress， neurotransmitter balance， and the EGFR tyrosine kinase inhibitor resistance signaling pathway.
